Cystic fibrosis in 2026: game over, or game on? Introduction to an AJRCCM special section on cystic fibrosis

Antenatal CFTR modulators to treat a healthy pregnant woman with a fetus affected by cystic fibrosis complicated by meconium ileus and intestinal volvulus: from a suspicion of the disease to a targeted treatment in utero: case report and narrative review

10.3390/jcm15051933 · 2026

Mucus and inflammation in the HEMT era: persistent barriers to complete airway normalization in cystic fibrosis

10.1016/j.jcf.2026.03.010 · 2026

Stop the asthma treatment elevator, we need to get off!

10.1164/rccm.202412-2431vp · 2025

Heterogeneity in response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis

10.1016/j.jcf.2024.04.013 · 2024

Can AI say “I don’t know”?

10.1056/nejmp2517624 · 2026

Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience

10.1378/chest.12-1430 · 2013

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study

10.1093/ajrccm/aamaf001 · 2026

CFTR modulators and rare variants-leaping from laboratory cells to real world effectiveness?

10.1093/ajrccm/aamaf102 · 2026